May 12, 2004

New Harvard Study

New Harvard Schizophrenia Study Initiated - Volunteers Needed

Researchers at Harvard Medical School are studying a new way of treating schizophrenia. Current medications only treat the symptoms of schizophrenia, not the cause. The treatment we are studying may result in a more lasting improvement of symptoms by normalizing a biological process that is thought to be irregular in this disorder. This treatment involves taking an FDA-approved medication, in addition to the subject´┐Żs current medication.

We are recruiting subjects who are:
- schizophrenic
- 18-25 years old
- taking risperidone (Risperdal)
- Live in the Boston Area

Compensation up to $250 will be provided to the participants.

For more information, please call Andrea at 617-998-5010

The study will take place in Boston, so participants must live close enough to come in for weekly visits. The study will last approximately 7 months. For six months, study participants will be taking the study drug (tiagabine) or placebo. For three months the visits to our office will be weekly, then only once a month for an additional three months. There will also be an MRI scan at the beginning and end of the study. The study is a double-blind, placebo-controlled, add-on design. Participants must be 18-25 years old, schizophrenic, and on risperidone.


* indicates required